Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib with Bendamustine and Rituximab in Untreated Indolent Lymphoma
NCT01029730Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Mar 2010
- Primary completion
- Oct 2014
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in lymphoma, sponsored by SCRI Development Innovations. Started Mar 2010; status: completed.
02
Drugs
bortezomib
03
Conditions
lymphoma
Beyond the preview
Go deeper on NCT01029730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01029730.